Suvaxyn Circo

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

porcine circovirus vaccine (inactivated, recombinant)

Available from:

Zoetis Belgium SA

ATC code:

QI09AA07

INN (International Name):

porcine circovirus vaccine (inactivated, recombinant)

Therapeutic group:

Pigs (for fattening)

Therapeutic area:

Immunologicals for suidae, Inactivated viral vaccines

Therapeutic indications:

For active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (PCV2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with PCV2.,

Product summary:

Revision: 2

Authorization status:

Authorised

Authorization date:

2018-02-07

Patient Information leaflet

                                15
B. PACKAGE LEAFLET
16
PACKAGE LEAFLET:
SUVAXYN CIRCO EMULSION FOR INJECTION FOR PIGS
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE,
IF DIFFERENT
Marketing authorization holder and manufacturer responsible for batch
release:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIUM
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Suvaxyn Circo emulsion for injection for pigs
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
One dose (2 ml) contains:
ACTIVE SUBSTANCES:
Inactivated recombinant chimeric porcine circovirus type 1containing
the porcine
circovirus type 2 ORF2 protein
2.3 – 12.4 RP*
ADJUVANT:
Squalane
Poloxamer 401
Polysorbate 80
8 µl (0.4% v/v)
4 µl (0.2% v/v)
0.64 µl (0.032%
v/v)
EXCIPIENTS:
Thiomersal
0.2 mg
*
Relative potency unit determined by ELISA antigen quantification (
_in vitro _
potency test) compared to a
reference vaccine.
White homogenous emulsion.
4.
INDICATION(S)
For active immunisation of pigs from 3 weeks of age against Porcine
Circovirus type 2 (PCV2) to
reduce viral load in blood and lymphoid tissues and fecal shedding
caused by infection with PCV2.
Onset of immunity: from 3 weeks after vaccination.
Duration of immunity: 23weeks after vaccination
5.
CONTRAINDICATIONS
None.
17
6.
ADVERSE REACTIONS
A transient increase in body temperature (on average 1 °C) is very
common during the first 24 hours after
vaccination. In individual pigs the temperature increase compared to
pre-treatment may commonly exceed
2 °C. This resolves spontaneously within 48 hours without treatment.
Immediate mild hypersensitivity-like
reactions may occur uncommonly after vaccination, resulting in
transient clinical signs such as vomiting,
diarrhea or depression. These clinical signs normally resolve without
treatment. Anaphylaxis may occur in
very rare cases. In case of such reactions, appropriate treatment is
recommended.
Local tissue reactions in the form of swelling at the injection site,
which m
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Suvaxyn Circo emulsion for injection for pigs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose (2 ml) contains:
ACTIVE SUBSTANCE:
Inactivated recombinant chimeric porcine circovirus type 1 containing
the
porcine circovirus type 2 ORF2 protein
_ _
2.3 – 12.4 RP*
ADJUVANT:
Squalane
Poloxamer 401
Polysorbate 80
EXCIPIENTS:
8 µl (0.4% v/v)
4 µl (0.2% v/v)
0.64 µl (0.032%
v/v)
Thiomersal
0.2 mg
*
Relative potency unit determined by ELISA antigen quantification (
_in vitro _
potency test) compared to a
reference vaccine.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Emulsion for injection.
White homogenous emulsion.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Pigs (for fattening)
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of pigs from 3 weeks of age against porcine
circovirus type 2 (PCV2) to reduce viral
load in blood and lymphoid tissues and fecal shedding caused by
infection with PCV2.
Onset of immunity: from 3 weeks after vaccination.
Duration of immunity: 23 weeks after vaccination
4.3
CONTRAINDICATIONS
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Vaccinate healthy animals only.
3
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
None
Special precautions to be taken by the person administering the
veterinary medicinal product to animals
Not applicable.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
A transient increase in body temperature (on average 1°C) is very
common during the first 24 hours after
vaccination. In individual pigs the temperature increase compared to
pre-treatment may commonly exceed
2 °C. This resolves spontaneously within 48 hours without treatment.
Immediate mild hypersensitivity-like reactions may occur uncommonly
after vaccination, resulting in
transient clinical signs such as vomiting, diarrhea or depression.
These clinical signs normally resolve without
treatment. Anaphylaxis may occur in very rar
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 06-11-2018
Summary of Product characteristics Summary of Product characteristics Bulgarian 06-11-2018
Public Assessment Report Public Assessment Report Bulgarian 20-04-2018
Patient Information leaflet Patient Information leaflet Spanish 06-11-2018
Public Assessment Report Public Assessment Report Spanish 20-04-2018
Patient Information leaflet Patient Information leaflet Czech 06-11-2018
Public Assessment Report Public Assessment Report Czech 20-04-2018
Patient Information leaflet Patient Information leaflet Danish 06-11-2018
Public Assessment Report Public Assessment Report Danish 20-04-2018
Patient Information leaflet Patient Information leaflet German 06-11-2018
Public Assessment Report Public Assessment Report German 20-04-2018
Patient Information leaflet Patient Information leaflet Estonian 06-11-2018
Public Assessment Report Public Assessment Report Estonian 20-04-2018
Patient Information leaflet Patient Information leaflet Greek 06-11-2018
Public Assessment Report Public Assessment Report Greek 20-04-2018
Patient Information leaflet Patient Information leaflet French 06-11-2018
Public Assessment Report Public Assessment Report French 20-04-2018
Patient Information leaflet Patient Information leaflet Italian 06-11-2018
Public Assessment Report Public Assessment Report Italian 20-04-2018
Patient Information leaflet Patient Information leaflet Latvian 06-11-2018
Public Assessment Report Public Assessment Report Latvian 20-04-2018
Patient Information leaflet Patient Information leaflet Lithuanian 06-11-2018
Summary of Product characteristics Summary of Product characteristics Lithuanian 06-11-2018
Public Assessment Report Public Assessment Report Lithuanian 20-04-2018
Patient Information leaflet Patient Information leaflet Hungarian 06-11-2018
Summary of Product characteristics Summary of Product characteristics Hungarian 06-11-2018
Public Assessment Report Public Assessment Report Hungarian 20-04-2018
Patient Information leaflet Patient Information leaflet Maltese 06-11-2018
Public Assessment Report Public Assessment Report Maltese 20-04-2018
Patient Information leaflet Patient Information leaflet Dutch 06-11-2018
Public Assessment Report Public Assessment Report Dutch 20-04-2018
Patient Information leaflet Patient Information leaflet Polish 06-11-2018
Public Assessment Report Public Assessment Report Polish 20-04-2018
Patient Information leaflet Patient Information leaflet Portuguese 06-11-2018
Summary of Product characteristics Summary of Product characteristics Portuguese 06-11-2018
Public Assessment Report Public Assessment Report Portuguese 20-04-2018
Patient Information leaflet Patient Information leaflet Romanian 06-11-2018
Public Assessment Report Public Assessment Report Romanian 20-04-2018
Patient Information leaflet Patient Information leaflet Slovak 06-11-2018
Public Assessment Report Public Assessment Report Slovak 20-04-2018
Patient Information leaflet Patient Information leaflet Slovenian 06-11-2018
Summary of Product characteristics Summary of Product characteristics Slovenian 06-11-2018
Public Assessment Report Public Assessment Report Slovenian 20-04-2018
Patient Information leaflet Patient Information leaflet Finnish 06-11-2018
Public Assessment Report Public Assessment Report Finnish 20-04-2018
Patient Information leaflet Patient Information leaflet Swedish 06-11-2018
Public Assessment Report Public Assessment Report Swedish 20-04-2018
Patient Information leaflet Patient Information leaflet Norwegian 06-11-2018
Summary of Product characteristics Summary of Product characteristics Norwegian 06-11-2018
Patient Information leaflet Patient Information leaflet Icelandic 06-11-2018
Summary of Product characteristics Summary of Product characteristics Icelandic 06-11-2018
Patient Information leaflet Patient Information leaflet Croatian 06-11-2018
Public Assessment Report Public Assessment Report Croatian 20-04-2018

Search alerts related to this product

View documents history